絞り込み

17094

広告

「"Rutkowski P "[Author]」の検索結果

365件中 41件~60件表示    検索結果をPubMedで見る PubMedで見る

Prognostic and predictive value of AJCC-8 staging in the phase III EORTC1325/KEYNOTE-054 trial of pembrolizumab vs placebo in resected high-risk stage III melanoma.

Natural history of well-differentiated liposarcoma of the extremity compared to patients treated with surgery.

Five-Year Outcomes with Dabrafenib plus Trametinib in Metastatic Melanoma.

Defining Rupture in Gastrointestinal Stromal Tumor: Semantics and Prognostic Value.

Correction: Use of extracellular vesicles from lymphatic drainage as surrogate markers of melanoma progression and mutation.

Use of extracellular vesicles from lymphatic drainage as surrogate markers of melanoma progression and mutation.

Comparison of Fatty Acid Profiles in a Group of Female Patients with Chronic Kidney Diseases (CKD) and Metabolic Syndrome (MetS)⁻Similar Trends of Changes, Different Pathophysiology.

Detection of SS18-SSX1/2 fusion transcripts in circulating tumor cells of patients with synovial sarcoma.

Defining Tumor Rupture in Gastrointestinal Stromal Tumor.

Evaluation of Two Dosing Regimens for Nivolumab in Combination With Ipilimumab in Patients With Advanced Melanoma: Results From the Phase IIIb/IV CheckMate 511 Trial.

Predicting Survival in Patients Undergoing Resection for Locally Recurrent Retroperitoneal Sarcoma: A Study and Novel Nomogram from TARPSWG.

Five-year outcomes from a phase 3 METRIC study in patients with BRAF V600 E/K-mutant advanced or metastatic melanoma.

Radiotherapy for retroperitoneal liposarcoma: A report from the Transatlantic Retroperitoneal Sarcoma Working Group.

An open-label, multicentre safety study of vemurafenib in patients with BRAF-mutant metastatic melanoma: final analysis and a validated prognostic scoring system.

Rational combination of cancer immunotherapy in melanoma.

Gastrointestinal Stromal Tumors.

Is the Surgical Margin in Gastrointestinal Stromal Tumors Different?

Gastrointestinal Stromal Tumors.

A prospective, observational safety study of patients with BRAF -mutated unresectable or metastatic melanoma treated with vemurafenib [Zelboraf Safety Study (ZeSS)].

Survival Outcomes in Patients With Previously Untreated BRAF Wild-Type Advanced Melanoma Treated With Nivolumab Therapy: Three-Year Follow-up of a Randomized Phase 3 Trial.

  1. 1
  2. 2
  3. 3
  4. 4
  5. 5
  6. 6
  7. 7
  8. 8
  9. 9
  10. 10
Sort by
※並べ替えは表示に時間がかかります